Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cholestin Arguments Scheduled for May 10


Cholestin Arguments Scheduled for May 10

WASHINGTON--The Food and Drug Administration (FDA) is scheduled to argue the marketing of Cholestin as a dietary supplement on May 10. The arguments are an attempt on the part of the FDA to reverse the decision of a Salt Lake City judge regarding a red yeast rice supplement that contains lovastatin. According to the FDA, that ingredient, present in Cholestin and in prescription cholesterol-reducing medications such as Merck's Mevacor, is a drug.

TAGS: Heart Health
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.